Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Omnicell Inc (OMCL)

Omnicell Inc (OMCL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,144,930
  • Shares Outstanding, K 41,938
  • Annual Sales, $ 787,310 K
  • Annual Income, $ 37,730 K
  • 60-Month Beta 1.08
  • Price/Sales 3.94
  • Price/Cash Flow 25.37
  • Price/Book 3.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.61
  • Number of Estimates 4
  • High Estimate 0.65
  • Low Estimate 0.59
  • Prior Year 0.55
  • Growth Rate Est. (year over year) +10.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.78 +4.46%
on 10/31/19
78.27 -8.20%
on 10/21/19
-4.22 (-5.55%)
since 10/18/19
3-Month
68.54 +4.83%
on 09/04/19
78.27 -8.20%
on 10/21/19
+1.35 (+1.91%)
since 08/16/19
52-Week
56.96 +26.14%
on 12/24/18
92.59 -22.40%
on 06/21/19
-0.97 (-1.33%)
since 11/16/18

Most Recent Stories

More News
SYNH vs. OMCL: Which Stock Should Value Investors Buy Now?

SYNH vs. OMCL: Which Stock Is the Better Value Option?

SYNH : 50.97 (-0.72%)
OMCL : 71.85 (-4.19%)
Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View

Omnicell (OMCL) continues to see solid segmental contributions in Q3. Expansion of gross and operating margins is a positive too.

OMCL : 71.85 (-4.19%)
TMO : 300.99 (-1.90%)
ISRG : 569.09 (-0.08%)
RMD : 147.78 (+0.46%)
Omnicell (OMCL) Q3 Earnings Surpass Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 5.56% and -1.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

OMCL : 71.85 (-4.19%)
Omnicell: 3Q Earnings Snapshot

MOUNTAIN VIEW, Calif. (AP) _ Omnicell Inc. (OMCL) on Thursday reported third-quarter earnings of $20 million.

OMCL : 71.85 (-4.19%)
Omnicell Achieves Record Revenue in the Third Quarter 2019

--GAAP net income per diluted share of $0.46, up 39.4% year-over-year

OMCL : 71.85 (-4.19%)
Med Center Health Formalizes Partnership With Omnicell to Drive Efficiency With Automated Medication Management

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced that Med Center Health has signed a sole...

OMCL : 71.85 (-4.19%)
Omnicell to Release Third Quarter 2019 Earnings Results on October 24, 2019

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Thursday, October 24, 2019,...

OMCL : 71.85 (-4.19%)
Mercy Selects Omnicell to Automate and Digitize Medication Management

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Mercy, one of the top five U.S. health systems...

OMCL : 71.85 (-4.19%)
Outlook on the World Pharmacy Automation Market, 2024 - Leading Companies are Baxter International, Becton, Dickinson & Co, Cerner Corp, Omnicell, and Parata Systems

The "Pharmacy Automation: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

CERN : 67.61 (-1.15%)
OMCL : 71.85 (-4.19%)
Omnicell Advances on Global Footing Despite Severe Rivalry

Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.

OMCL : 71.85 (-4.19%)
SYK : 205.06 (-0.58%)
NUVA : 72.59 (-1.06%)
AMED : 154.92 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade OMCL with:

Business Summary

Omnicell, Inc. is a leading provider of medication and supply management automation, analytics software, and medication adherence solutions for healthcare organizations. It works with healthcare providers to drive operational efficiency by removing tedious tasks and waste. Regardless of distribution...

See More

Key Turning Points

2nd Resistance Point 76.12
1st Resistance Point 73.99
Last Price 71.85
1st Support Level 70.73
2nd Support Level 69.60

See More

52-Week High 92.59
Fibonacci 61.8% 78.98
Fibonacci 50% 74.77
Last Price 71.85
Fibonacci 38.2% 70.57
52-Week Low 56.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar